Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

80 mg/m2 IV administered on Days 1, 8, 15 of each 21-day cycle

Carboplatin AUC 1.5 IV administered on Days 1, 8, 15 of each 21-day cycle

Trastuzumab 8 mg/kg loading dose, followed by 6 mg/kg maintenance dose, administered on Day 1 of each 21-day cycle

Pertuzumab 840 mg loading dose, followed by 420 mg maintenance dose, administered on Day 1 of each 21-day cycle

60 mg/m2 IV administered on Day 1 of each 14-day cycle

600 mg/m2 IV administered on Day 1 of each 14-day cycle

"Either 200 mg IV administered on Day 1 of Cycles 1-4, or 400 mg IV administered on Day 1 of Cycles 1 and 3 of the paclitaxel/carboplatin regimen.~400 mg on Day 1 of Cycles 1 and 4 of the dose-dense AC regimen."

Can be used in place of separate IV formulations of pertuzumab and trastuzumab. 1200 mg pertuzumab/600 mg trastuzumab/30,000 U hyaluronidase administered subcutaneously on Day 1 of the first cycle, followed by a maintenance dose of 600 mg pertuzumab/600 mg trastuzumab/20,000 U hyaluronidase administered subcutaneously every 3 weeks.